Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Novo Nordisk Stories

2013-09-06 23:21:39

d’Oliveira & Associates has posted a new infographic about the type-2 diabetes drug Victoza. The law firm now works with experienced lawyers, who are filing cancer lawsuits. (PRWEB) September 06, 2013 Victoza (liraglutide) is a once-daily injection used to control blood sugar levels in type-2 diabetes patients. This medicine increases insulin while making the stomach feel full. The FDA approved this drug in January 2010 and it earned more than $2.3 billion in sales its first year...

2013-09-06 12:21:58

BOSTON, Sept. 6, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest Type 1 Diabetes (T1DM) competitive landscape map. This particular landscape highlights 71 international companies with over 140 drugs and devices currently on the market and in development. (Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) Topics include: -- Save the cells: immune therapies for T1DM -- Beta-cell regeneration strategies -- Pancreatic replacement via...

2013-09-03 04:21:17

CAMBRIDGE, England, September 3, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised GBP15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Board of Acacia...

2013-08-29 23:02:45

The firm is currently evaluating Byetta, Victoza and Januvia lawsuits for those who have suffered from the drugs’ alleged potentially serious side effects, such as pancreatic cancer and thyroid cancer. (PRWEB) August 29, 2013 Byetta, Januvia and Victoza lawsuits were consolidated on Aug. 28 in federal district court in California, according to court documents. The Rottenstein Law Group LLP, a diabetes drug law firm, explains what this means for those looking to file lawsuits over the...

2013-08-21 12:27:19

First insulin injection device to combine half-unit dosing with a memory function to help patients better manage their diabetes PLAINSBORO, N.J., Aug. 21, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the insulin device NovoPen Echo(®). This marks the first and only pen device in the U.S. with half-unit dosing and a memory function that records the dose and time passed...

2013-08-06 08:21:25

Charlie Kimball Makes History as First Driver with Diabetes to Win an IndyCar Race PLAINSBORO, N.J., Aug. 6, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, is pleased to announce that Charlie Kimball, driver of the No. 83 NovoLog(®) FlexPen(®) Honda, has become the first and only licensed driver with diabetes to win an IndyCar race. This milestone was achieved as the Novo Nordisk Chip Ganassi Racing Team saw its first-ever IndyCar Series victory, secured at the...

2013-08-02 12:24:38

Novo Nordisk Community Care Program Now Accepting Applications - Rochester, Minnesota Organizations Invited to Apply ROCHESTER, Minn., Aug. 2, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that it is now accepting applications from local Rochester, Minnesota nonprofit organizations for 2013 Novo Nordisk Community Care sponsorships. Through the sponsorships, Novo Nordisk will invest $80,000 to support local organizations that educate people living...

2013-08-01 16:30:56

At this time, please disregard the news release, Novo Nordisk To Award $80,000 To Local Programs That Help People Living With Diabetes In Rochester As Part Of Educational Initiative, issued 01-Aug-2013 over PR Newswire. SOURCE Novo Nordisk

2013-08-01 12:28:58

Novo Nordisk Community Care Program Now Accepting Applications - Seattle Organizations Invited to Apply SEATTLE, Aug. 1, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that it is now accepting applications from local Seattle nonprofit organizations for 2013 Novo Nordisk Community Care sponsorships. Through the sponsorships, Novo Nordisk will invest $80,000 to support local organizations that educate people living with type 2 diabetes. For more...

2013-08-01 12:28:57

Novo Nordisk Community Care Program Now Accepting Applications - Portland Organizations Invited to Apply PORTLAND, Ore., Aug. 1, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that it is now accepting applications from local Portland nonprofit organizations for 2013 Novo Nordisk Community Care sponsorships. Through the sponsorships, Novo Nordisk will invest $80,000 to support local organizations that educate people living with type 2 diabetes. For...